A Phase I-II Study of R115777 (Tipifarnib, Zarnestraâ) Plus Sequential Weekly Paclitaxel followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer

Study Status

Open to Enrollment

Study Description

This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with combination chemotherapy and to see how well they work in treating patients with stage II or stage III breast cancer.

Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib together with combination chemotherapy may kill more tumor cells.

Disease Status and/or Stage

Stage IIB-IIC Breast Cancer

Sponsor

New York Cancer Consortium; National Cancer Institute

Key Eligibility

  • Age 18 and older
  • Diagnosed with breast cancer, Stages IIB, IIIA, IIIB, or IIIC
  • Other eligibility criteria will be discussed with you when you contact the study team

Principal Investigator

Linda Vahdat, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (212) 746-9498
roh2026@med.cornell.edu

Top of page